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20 The Journal of Thoracic and CardiovObjective: We evaluated, in a randomized controlled trial, the safety and effective-
ness of intraoperative cell salvage and autotransfusion of washed salvaged red blood
cells after first-time coronary artery bypass grafting performed on the beating heart.
Methods: Sixty-one patients undergoing off-pump coronary artery bypass grafting
surgery were prospectively randomized to autotransfusion (n  30; receiving
autotransfused washed blood from intraoperative cell salvage) or control (n  31;
receiving homologous blood only as blood-replacement therapy). Homologous
blood was given according to unit protocols.
Results: The groups were well matched with respect to demographic and comorbid
characteristics. Patients in the autotransfusion group had a significantly higher
24-hour postoperative hemoglobin concentration (11.9 g/dL; SD, 1.41 g/dL) than
those in the control group (10.5 g/dL; SD, 1.37 g/dL) (mean difference, 1.02 g/dL;
95% confidence interval, 1.60-0.44 g/dL; P  .0007), as well as a 20% reduction in
the frequency of homologous blood product use (11/31 vs 5/30; P  .095).
Autotransfusion of washed red blood cells was not associated with any derangement
of thromboelastograph values or laboratory measures of clotting pathway function
(prothrombin time, activated partial thromboplastin time, and fibrinogen levels),
increased postoperative bleeding, fluid requirements, or adverse clinical events.
There was no statistical difference between groups in the total operation, hospital-
ization, and management costs per patient (median difference, $1015.90 [US dol-
lars]; 95% confidence interval, $2260 to $206; P  .11).
Conclusions: Intraoperative cell salvage and autotransfusion was associated with
higher postoperative hemoglobin concentrations, a modest reduction in transfusion
requirements, no adverse clinical or coagulopathic effects, and no significant in-
crease in cost compared with controls. This study supports its routine use in
off-pump coronary artery bypass grafting surgery.
Reinfusion of salvaged autologous blood after conventional coronary arterybypass grafting (CABG) with cardiopulmonary bypass (CPB) has beenshown to reduce homologous blood exposure without any increase in
adverse events, coagulopathy, or hospitalization costs.1-3 It remains unclear, how-
ever, whether this is also true for CABG performed on the beating heart (off-pump
CABG; OPCAB). In comparison to conventional CABG, OPCAB is associated with
a significant reduction in perioperative blood loss, homologous blood and blood
product use, and postoperative morbidity,4-6 and this may reduce any benefit of cell
salvage in this setting. It is also possible that any potential coagulopathic effects of
autotransfused washed red blood cells, not evident against the background noise of
the abnormal clotting evident after CPB, may be more clinically relevant after
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effects of intraoperative cell salvage and autotransfusion on
postoperative hemostasis, homologous blood exposure, and
cost in OPCAB surgery in a randomized controlled trial.
Patients and Methods
Study Population and Patient Allocation
Sixty-one patients admitted to our institution for CABG consented
to enrollment in the study over a 16-month period. Male or female
patients aged 18 years or more and who were undergoing non-
emergency first-time CABG were eligible to take part. Exclusion
criteria included patients who are prevented from receiving blood
and blood products according to a system of beliefs (eg, Jehovah
Witnesses); patients receiving preoperative warfarin, heparin, or
other systemic anticoagulant drugs; patients with congenital or
acquired platelet, red blood cell, or clotting disorders; patients with
ongoing or recurrent systemic sepsis; and patients who were un-
able to give full informed consent for the study (eg, because of
learning or language difficulties). The study received local ethics
committee approval. Patients were assigned to 1 of 2 randomized
groups, autotransfusion or control, in a 1:1 ratio by using block
randomization. Allocations were generated by a card system and
concealed in sealed opaque envelopes. Patients who had given
consent were randomized immediately before surgery. Clinical
outcome data were collected prospectively as part of our patient
analysis and tracking system.
The study was powered to detect a significant effect of auto-
transfusion on postoperative clotting profiles. This was chosen in
preference to the frequency of homologous blood usage, as using
data derived from a previous study,4 it was calculated that this
would have required as many as 660 patients to achieve adequate
power. Our previous studies of clotting profiles and hematologic
and biochemical indices in OPCAB patients4,7,8 had shown sig-
nificant differences in outcomes with sample sizes of 20 patients in
each group. Using these data, we predicted that a randomized
study of 40 patients in total would allow a 90% chance of detecting
a standardized difference of more than 1 in laboratory measures of
clotting pathway function and hematologic indices with 95% con-
fidence. For the purposes of this study, we recruited a total of 30
patients in each arm to allow for possible dropouts.
Cell-Salvage Protocol
Patients in the autotransfusion group underwent intraoperative cell
salvage, with autotransfusion of washed, salvaged red blood cells
at the completion of the operative procedure. All blood lost, from
skin incision to skin closure, was salvaged via a single-lumen
suction tube flushed with heparinized 0.9% saline (10 U/mL in-
fused at 83 mL/h) and connected to the closed rigid collection
chamber of a Dideco Compact autotransfuser device (Dideco,
Gloucester, United Kingdom) at high-pressure suction. Before
autotransfusion, the heparinized salvaged intraoperative blood un-
derwent a washing process, with resuspension of the red blood
cells in saline, to a hematocrit of approximately 0.6. This red blood
cell suspension was then transferred to a sterile collecting bag that
was disconnected from the autotransfuser and administered via a
standard blood-giving set. Salvaged washed red blood cells were
autotransfused at the time of skin closure.
The Journal of ThoracIn the control group, all blood spilled, from skin incision to skin
closure, was aspirated with a high-pressure sucker and discarded.
Perioperatively all patients were administered homologous, leu-
kodepleted packed red blood cells as blood-replacement therapy,
according to predefined unit protocols. The threshold for transfu-
sion of homologous blood was hemoglobin less than 8 g/dL or
hematocrit less than 0.23. In patients with excessive blood loss and
cardiovascular instability, blood was given at the discretion of
anesthetic or intensive care unit (ICU) staff. Clotting products and
platelets were administered at the discretion of the ICU staff in
response to bleeding in the presence of coagulopathy or dimin-
ished platelet count.
In both groups, after closure of the sternum, postoperative
mediastinal drainage was achieved by 28F single-lumen rigid
sump drains (n  1-3) to a 1000-mL sterile collection chamber
connected to 20 cm H2O wall suction via an underwater seal, from
which all subsequent shed mediastinal fluid loss was then re-
corded. This collected blood was discarded.
Operative Technique
The anesthetic technique was standardized for all patients and
has been reported previously.4 Heparin (150 IU/kg) was admin-
istered before the start of the first anastomosis to achieve an
activated clotting time greater than 300 seconds. On completion
of all anastomoses, protamine was given (1:1 ratio) to reverse
the effect of heparin and return the activated clotting time to
preoperative levels. The method of exposure and stabilization
used to perform the anastomoses has been described previous-
ly.9-11 The target vessel was exposed and snared above the
anastomotic site by using a 4-0 Prolene (Ethicon, Inc, Somer-
ville, NJ) suture with a soft plastic snugger to prevent coronary
injury. The coronary artery was then opened, and the anasto-
mosis was performed. An intracoronary shunt (Anastoflo Intra-
vascular Shunt; Research Medical Inc, Midvale, Utah) was used
to perform each anastomosis, to reduce blood loss and regional
ischemia.11 No patient had predonated autologous blood for
perioperative use.
Laboratory and Bedside Measurements of Clotting
Pathway and Platelet Function
Hemoglobin concentration, hematocrit, platelet count, measure-
ments of clotting pathway function (international normalized ratio
of the prothrombin time, a measure of the extrinsic and common
clotting pathways; and activated partial thromboplastin time
[APTT], expressed as the APTT ratio to a normalized control
value, a measure of the intrinsic and common clotting pathways),
serum fibrinogen levels, and thromboelastograms (TEG; Throm-
belastograph; Haemoscope Corp, Skokie, Ill) were performed be-
fore surgery, immediately after the administration of protamine, 1
hour after completion of the surgical procedure, and then at 24
hours after the procedure. TEG was performed on heparinized
celite-activated whole blood drawn from the arterial line. As part
of routine postoperative care, hemoglobin concentration and he-
matocrit were measured on arrival in the ICU and then at hourly
intervals, or as clinically indicated, via the indwelling arterial
cannula.
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The outcome variable was the total cost for both operative and
postoperative services. Professional fees, preoperative costs, oper-
ating room and perfusionist staff costs, and drug costs were ex-
TABLE 1. Patient characteristics
Variable
Control
(n  31)
Autotransfusion
(n  30)
Age (y) 66.4 (7.6) 62.3 (9.3)
Male 23 (74%) 25 (83%)
Diabetes treatment
Diet 0 2 (7%)
Insulin 1 (3%) 1 (3%)
Oral 3 (10%) 2 (7%)
Hypertension 22 (71%) 21 (70%)
Current smoker 3 (10%) 5 (17%)
COPD 8 (26%) 2 (7%)
Serum creatinine (mol/L) 95 (87.0-116.0) 100 (90.0-107.8)
Previous stroke/neurologic
dysfunction
4 (13%) 1 (3%)
Peripheral vascular disease 3 (10%) 2 (7%)
Body mass index (kg/m2) 28.0 (3.80) 28.8 (4.56)
Aspirin within 5 d before
surgery
11 (36%) 10 (33%)
CCS class (angina)
0/1 1 (3%) 6 (20%)
2 17 (55%) 5 (17%)
3 11 (36%) 8 (27%)
4 2 (7%) 11 (37%)
NYHA score (dyspnea)
I 10 (32%) 9 (30%)
II 9 (29%) 10 (33%)
III 11 (36%) 9 (30%)
IV 1 (3%) 2 (7%)
MI  1 mo of operation 0 4 (13%)
Congestive cardiac failure 0 2 (7%)
Vessels diseased
2 2 (7%) 3 (10%)
3 29 (93%) 27 (90%)
LMS stenosis 50% 4 (13%) 6 (20%)
Ejection fraction 30% 1 (3%) 3 (10%)
Urgent 12 (39%) 16 (53%)
Parsonnet score 5.0 (3.0-10.0) 5.0 (2.8-12.3)
EuroSCORE 3.0 (1.0-4.0) 2.5 (1.8-5.0)
No. grafts 3.0 (2.0-3.0) 3.0 (2.0-3.0)
Lowest core temperature (°C) 34.9 (34.5-35.2) 35.2 (34.4-35.4)
LITA 27 (87%) 29 (97%)
RITA 2 (7%) 0
Radial graft 5 (16%) 7 (23%)
Values represent numbers of patients with percentages, except for con-
tinuous variables, for which values are mean (SD) for normally distributed
data and median (interquartile range) for skewed data. COPD, Chronic
obstructive pulmonary disease; CCS, Canadian Cardiovascular Society;
NYHA, New York Heart Association; MI, myocardial infarction; LMS, left
main stem; LITA, left internal thoracic artery; RITA, right internal thoracic
artery.cluded. Variable and fixed direct costs were obtained for each care
22 The Journal of Thoracic and Cardiovascular Surgery ● July 2area and included the cost of operating room materials, bed occu-
pancy (which included nursing costs), transfusion products, and
postoperative complication management. Indirect costs such as
hospital administration, building, and maintenance costs were ex-
cluded. Patients transferred to an intermediate care facility before
home discharge were censored at the time of discharge from the
cardiothoracic unit. All costs are in US dollars with the exchange
rate calculated as of June 2004.
Statistical Analysis
Continuous measurements were assessed for normality of distri-
bution. If skewed, data are summarized as a median and interquar-
tile range; otherwise, a mean and SD are given. Data for the 2
groups were compared by using the Mann-Whitney test, and effect
sizes are expressed as a median difference or hazard ratio (time
measurements). Categorical data are reported as the number and
percentage and were compared by using the Pearson 2 test or
Fisher exact test (if expected frequencies were5). The odds ratio
was used to quantify the effect of autotransfusion. All effect sizes
are reported with 95% confidence intervals (CIs). Postrandomiza-
tion measurements of hemoglobin and platelet count and measures
of clotting pathway function were compared by using a mixed
regression model. All analyses were adjusted for prerandomization
(baseline) readings. A variety of models describing the correlations
between repeated measurements on the same patient were exam-
ined, and the structure that led to the lowest value for the Schwarz
bayesian information criterion was chosen in each case. Platelet
count and fibrinogen both followed a skewed distribution and were
transformed to the logarithmic scale for analysis. Model adequacy
was assessed graphically, and where outlying observations were
indicated, the model was refitted with the outlier(s) excluded.
Results are reported here with outliers excluded. Changes in treat-
ment effect over time were assessed with the F-test, and, if statis-
tically significant at the 10% level, the treatment difference is
reported separately at that time point. Otherwise, an overall effect
of treatment is given. Results are presented as least-squares means
and as a difference in means with 95% CIs. For platelet count and
fibrinogen, least-squares geometric means and the ratio of geomet-
ric means with 95% CIs are given. All data analysis was performed
with SPSS for Windows, version 9.0 (SPSS Inc, Chicago, Ill)
except for the mixed regression models, which were fitted by using
SAS version 8.2 (SAS Institute, Cary, NC).
Results
Baseline Characteristics
Preoperative and operative characteristics are shown in Ta-
ble 1. The 2 groups were balanced before surgery with
respect to demographics and comorbidity apart from a
higher frequency of unstable angina symptoms in the auto-
transfusion group. Parsonnet scores or EuroSCOREs were
similar for the 2 groups. Intraoperative characteristics were
also well matched. No patient received aprotinin during the
study. Ten patients in the autotransfusion group had cells
salvaged but had insufficient volume to merit processing
(150 mL). This blood was discarded; however, these
patients were included in the analysis on the basis of inten-
tion to treat.
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Autotransfusion Versus Control
Patients in the autotransfusion group received a median of
236 mL (interquartile range, 206-342 mL) of autotransfused
red blood cells after surgery. There was a statistical trend
toward a reduction in the frequency of exposure to homol-
ogous blood products in the autotransfusion group (P 
.095; Table 2). There was no difference between groups in
postoperative chest drainage, ventilation time, ICU stay, or
the frequency of serious morbidity. One patient in the au-
totransfusion group required 29 days of vacuum-assisted
drainage for a deep sternal wound infection that resolved
without operation. One patient in the control group had
sternal rewiring after a sternal dehiscence. Two patients in
TABLE 2. Postoperative outcome and homologous blood p
Outcome
Control
(n  31)
No. patients autotransfused
Volume salvaged (mL)
Volume autotransfused (mL)
Intraoperative homologous RBCs (units) 1 (3%)
Intraoperative platelets (units) 0
Intraoperative clotting products (units) 0
Intraoperative volume infused (mL) 2500 (2000-3000
In-hospital deaths 0
Ventilation time (h) 7.0 (5.0-10.0)
Intensive therapy unit stay (d) 1.0 (1.0-1.0)
High-dependency unit stay (d) 1.0 (1.0-3.0)
Total hospital stay (d) 6.0 (5.0-8.0)
Readmitted to ICU 1 (3%)
Postoperative inotropic support 14 (45%)
Arrhythmia 7 (23%)
Pulmonary complications 4 (13%)
Stroke 0
Infective complications 1 (3%)
Renal complications 2 (7%)
Myocardial infarction 0
Sternal rewiring 1 (3%)
Drainage in 24 h (mL) 725 (462-912)
Drainage total (mL) 787 (531-969)
Fluid balance at 24 h (mL) 724 (456-988)
No. patients receiving any blood product 11 (36%)
No. patients receiving homologous blood
transfusion
7 (23%)
No. patients receiving platelet transfusion 6 (19%)
No. patients receiving clotting factor transfusion 1 (3%)
Values represent numbers of patients with percentages. For categorical d
size is expressed as odds ratio (95% confidence interval [CI]). For contin
derived from the Mann-Whitney test; effect size is expressed as hazard rati
(95% CI for median difference) is given. RBC, Leukodepleted packed re
homologous red blood cells is approximately 280 mL. For patients in the c
and 4 units of RBCs. Six patients received 1 unit of platelets. In the autotran
One patient received 1 unit and one 2 units of platelets.the control group required noninvasive ventilation after
The Journal of Thoracextubation, and postoperative pneumonia developed in an-
other 2 patients.
Effect of Autotransfusion on Hematologic Indices and
Measures of Coagulation Pathway and Platelet
Function
The postoperative hemoglobin concentration was signif-
icantly higher in the autotransfusion patients. Hemoglo-
bin levels were similar in the 2 groups after protamine
administration and at 1 hour (P  .71 and P  .60,
respectively), but at 24 hours the mean level was, on
average, 1.02 g/dL lower in the control group (95% CI,
 1.60 to  0.44; P  .0007; Table 3). A similar differ-
ence was noted with hematocrit. At 24 hours, the mean
ct requirements
utotransfusion
(n  30)
Median difference (95% CI)
(control–autotransfusion)
Odds/hazard
ratio (95% CI)
P
value
20 (67%)
47 (607-978)
36 (206-342)
0 .99
2 (7%) .24
0
00 (2500-3000) 0 (500 to 0) .86
0
6.0 (4.8-8.0) 0.98 (0.59-1.65) .40
1.0 (1.0-1.0) 1.14 (0.67-1.96) .50
2.0 (1.0-3.0) 1.29 (0.73-2.29) .65
6.0 (5.0-8.3) 1.08 (0.65-1.80) .73
1 (3%) 1.0 (0.06-17.32) .98
14 (47%) 1.10 (0.38-2.92) .99
6 (20%) 0.86 (0.25-2.92) .81
0 .11
0
2 (7%) 2.14 (0.18-25.0) .61
0 .49
2 (7%) .24
0 .99
00 (463-900) 0 (150 to 225) .99
50 (469-913) 204.5 (238 to 498) .30
46 (252-950) 100 (75 to 275) .60
5 (17%) 0.36 (0.11-1.22) .095
4 (13%) 0.53 (0.14-2.03) .35
2 (7%) 0.30 (0.06-1.61) .26
0 .99
values were derived from the Pearson 2 or Fisher exact test, and effect
variables, values are medians (interquartile ranges), and P values were
CI) for time measurements. For all other measures, the median difference
od cells; ICU, intensive care unit. One unit of packed (hematocrit 0.6)
group, 5 patients received 1 unit of RBCs, and 1 patient each received 2
n group, 1 patient received 1 unit of RBCs, and 3 received 2 units of RBCs.rodu
A
7
2
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7
6
4
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sfusiohematocrit level was significantly lower (0.03 L/L) in the
ic and Cardiovascular Surgery ● Volume 130, Number 1 23
; SE i
Surgery for Acquired Cardiovascular Disease Murphy et al
A
CDcontrol group (95% CI, 0.049 to 0.013; P  .0008).
There was no difference between groups in the level of
intraoperative or postoperative hemodilution (Tables 2
TABLE 3. Hemoglobin concentration, platelet count, and m
effect sizes
Variable
LS mean (SE)
Control Autotransfusion
Hemoglobin (g/dL) (n  57)
After protamine 11.25 (0.21) 11.14 (0.21)
1 h 10.40 (0.20) 10.55 (0.21)
24 h 10.69 (0.20) 11.71 (0.21)
Hematocrit (L/L) (n  57)
After protamine 0.344 (0.006) 0.345 (0.006)
1 h 0.305 (0.006) 0.312 (0.006)
24 h 0.319 (0.006) 0.350 (0.006)
Platelet count (109/L) (n  60)*
1 h 189.7 (0.026)‡ 192.8 (0.028)‡
24 h 218.2 (0.026)‡ 225.4 (0.027)‡
Prothrombin ratio (n  58)
After protamine 1.27 (0.012) 1.27 (0.012)
1 h 1.19 (0.011) 1.19 (0.012)
24 h 1.15 (0.012) 1.15 (0.012)
APTT ratio (n  58)
After protamine 1.14 (0.022) 1.17 (0.024)
1 h 1.13 (0.022) 1.08 (0.022)
24 h 1.11 (0.022) 1.08 (0.022)
Fibrinogen (g/L) (n  58)*
After protamine 2.68 (0.033)‡ 2.59 (0.036)‡
1 h 2.34 (0.033)‡ 2.21 (0.034)‡
24 h 5.04 (0.034)‡ 4.92 (0.035)‡
R (min) (n  52)
After protamine 7.30 (0.37) 6.99 (0.38)
1 h 6.33 (0.37) 5.86 (0.38)
24 h 6.16 (0.38) 5.54 (0.38)
K (min) (n  52)
After protamine 2.27 (0.097) 2.22 (0.099)
1 h 2.34 (0.097) 2.05 (0.100)
24 h 1.90 (0.099) 1.86 (0.099)
Angle (radians) (n  52)
After protamine 1.14 (0.017) 1.14 (0.017)
1 h 1.15 (0.017) 1.18 (0.017)
24 h 1.23 (0.018) 1.20 (0.017)
MA (mm) (n  51)
After protamine 61.4 (1.09) 60.2 (1.10)
1 h 60.7 (1.09) 62.0 (1.11)
24 h 65.3 (1.11) 66.1 (1.11)
All analyses were adjusted for baseline readings. LS, Least squares; n, num
interval; APTT, activated partial thromboplastin time. For thromboelastogra
the analyzer to initial fibrin formation. It is an index of the clotting pathway
pathways. The K and angle values are measures of the rapidity of clot stre
is a direct function of the maximum dynamic properties of fibrin and platel
values are representative of platelet count and function, fibrinogen conce
scale for analysis. †Ratio of geometric means. ‡Geometric mean and SEand 3). There was no difference between groups for any
24 The Journal of Thoracic and Cardiovascular Surgery ● July 2of the laboratory clotting pathway indices or TEG pa-
rameters measured (Table 3) except for a possible time-
related difference between the 2 treatment groups for
res of clotting pathway function: response over time and
Difference/ratio 95% CI P value
0.11 0.47 to 0.70 .71
0.15 0.74 to 0.43 .60
1.02 1.60 to0.44 .0007
0.001 0.019 to 0.017 .91
0.007 0.024 to 0.011 .46
0.031 0.049 to0.013 .0008
0.98† 0.91 - 1.04 .44
0.004 0.028 to 0.019 .71
0.024 0.088 to 0.040 .47
0.057 0.004 to 0.12 .069
0.025 0.036 to 0.087 .42
1.04† 0.96 - 1.12 .27
0.47 0.32 to 1.27 .24
0.13 0.058 to 0.32 .17
0.0002 0.033 to 0.034 .99
0.29 2.69 to 2.11 .81
patients for whom all data were available at all time points; CI, confidence
analysis, R is the reaction time or the latency from placement of blood in
ades and, more specifically in this case, the intrinsic and common clotting
ning, whereas the MA, or maximum amplitude, of the thromboelastogram
ding and is a measure of the ultimate strength of the clot. Together these
ion, and efficacy of fibrin cross-linkage. *Transformed to the logarithmic
s on the logarithmic scale.easu
ber of
phic
casc
ngthe
et bon
ntratAPTT (P  .075). The APTT ratio was similar in the 2
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 .47 and P  .42, respectively), but at 1 hour, the mean
ratio was, on average, 0.057 lower in the control group
(95% CI, 0.004 to 0.12; P  .069).
Effects of Cell Salvage and Autotransfusion on
Procedural Costs
There was a significant difference in the median operative
cost per patient between the 2 groups (Table 4), and this was
attributed to the increased cost of the cell salvage consum-
ables in the autotransfusion group, although this effect was
minimized by not processing small volumes of blood. There
was no difference in bed and nursing costs or complication-
management costs (Table 4). Transfusion costs were less in
the autotransfusion group; however, this was not statisti-
cally significant. The increase in operative costs as a result
of using the cell salvage device did not result in a statisti-
cally significant increase in overall costs.
Discussion
In this randomized study, intraoperative cell salvage was
associated with higher postoperative hemoglobin concentra-
tions, a modest reduction in transfusion requirements, no
adverse clinical or coagulopathic effects, and no significant
increase in total cost compared with controls. The benefits
of a higher postoperative hemoglobin are intuitive, because
ultimately this will result in lower homologous transfusion
rates. Cell salvage and autotransfusion of blood spilled
during surgery resulted in higher postoperative hemoglobin
concentrations. As a result, fewer autotransfused patients
reached the transfusion trigger (hematocrit 0.23), and
fewer received transfusions. The observed 19% reduction in
overall homologous blood component use in the autotrans-
fusion group, although not statistically significant (P 
.095), seems to us clinically relevant, particularly when one
considers the low-transfusion-risk patient cohort and surgi-
cal technique (OPCAB), which will both have contributed
to low overall homologous blood requirements.4,7,12 The
observed effect size of cell salvage on homologous red
blood cell use was a reduction of 10%. We calculated that
for any future study to detect a difference of this magnitude,
given a 23% transfusion rate in the control group, 90%
power, and a 2-sided 5% level of statistical significance, a
total of 660 patients (330 per group) would be required. It is
also possible that the effect size would have been greater
had patients at higher risk of bleeding, such as unstable
patients receiving preoperative heparin or clopidrogrel,
been enrolled in the study. These patients were excluded,
however, because of the greater variability observed in their
perioperative clotting profiles.
Avoidance of homologous blood transfusion is not the
only benefit of higher postoperative hemoglobin concentra-
tions. Low intraoperative and postoperative hematocrit has
been associated with both significantly increased mortality
The Journal of Thoracand severe morbidity, including low cardiac output syn-
drome, intra-aortic balloon pump use, and renal failure
requiring dialysis.13,14 In contrast, one study has suggested
that hyperviscosity might contribute to graft thrombosis.
Spiess and colleagues15 demonstrated an association be-
tween a high postoperative hematocrit (0.34) and postop-
erative myocardial infarction in patients after conventional
CABG with CPB. The validity of this analysis has subse-
quently been questioned, however,16 and such a prothrom-
botic effect, if any, would have to be compared with the
well-documented benefits of avoiding homologous blood
transfusion.
Historically, autotransfusion has been associated with
increased bleeding and coagulopathy, the so-called
salvaged-cell syndrome.17 This has been addressed by mod-
ern cell-salvage and -washing systems, which effectively
remove activated leukocytes, platelets, and inflammatory
mediators from salvaged blood.18-20 Concern remains, how-
ever, that even washed cells may have a coagulopathic
effect. A randomized study demonstrated that postoperative
autotransfusion of washed red blood cells increased serum
fibrinogen levels, as well as prothrombin and APTT times,
after CABG with CPB.3 Similarly, retransfusion of cell
salvage–washed red blood cells from the residual extracor-
poreal circuit blood after coronary bypass has been shown
to result in deranged coagulation on laboratory testing.19,20
Interpretation of these studies in on-pump patients is made
difficult because of the background noise from increased
fibrinolysis, platelet activation, and clotting factor consump-
tion associated with CPB,21,22 and clinical studies do not
support any clinically significant effect of these apparent
changes on blood loss or transfusion requirements after
washed red blood cell autotransfusion.1-3 OPCAB results in
reduced thrombin generation, reduced fibrinolytic activity,
and better overall preservation of hemostasis compared with
conventional CABG22,23 and serves as a better template to
assess any derangement of hemostasis resulting from auto-
transfusion. These data demonstrate that, on routine use in
OPCAB patients, there was no detectable coagulopathic or
thrombotic effect of intraoperatively salvaged, washed red
blood cells. Furthermore, there was no increase in bleeding
or thrombotic events. We therefore conclude that autotrans-
fusion is safe and effective.
Cell salvage was not associated with any significant
increase in total cost, and although the power of this study
to exclude a type II error in this respect is limited, these
findings are noteworthy for several reasons. First, in addi-
tion to these immediate costs, homologous blood transfu-
sion has additional indirect long-term and remote costs that
were not considered in this analysis. For example, the
annual costs of routine medical care, excluding emergency
admissions and liver transplantation, for a patient with trans-
fusion-associated hepatitis C infection in the United States in
ic and Cardiovascular Surgery ● Volume 130, Number 1 25
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CD1995 was $12,000.24 Although transfusion-associated hepatitis
C transmission is now very rare, new bloodborne pathogens
(prions, West Nile virus, and transfusion-transmitted virus)
are continuously emerging,24,25 and the relative cost benefit
TABLE 4. Perioperative costs
Variable Control (n  31)
Operation costs No. Total cost
Procedure trays 31 7042.73
Sutures/disposables 17,169.04
Blower 31 2281.60
Radial/leg trays 36 677.64
Autotransfuser disposables
Reservoir
Centrifuge
Total operation cost 27,171.00
Mean cost 876.50
Median cost (IQR) 873.40
(873.40-873.40
Bed occupancy and nursing cost 24-h shifts Total cost
ICU cost 31 99,420.72
HDU cost 52 64,679.68
Ward cost 220 79,037.20
Total bed occupancy cost 243,137.60
Mean cost 7843.20
Median cost (IQR) 7131.80
(5888.00-8541.7
Complication costs No. Total cost
IABP 1 1019.36
Rewiring 1 445.28
Echocardiography 2 393.76
Wound infection dressing 454.48
Total complication costs 2312.88
Mean complication costs 74.60
Median cost (IQR) 0 (0-0)
Transfusion costs No. Total cost
Units of homologous RBCs 11 2469.28
FFP 6 1876.80
PLT 2 128.80
Total transfusion costs 4474.88
Mean transfusion costs 144.35
Median cost (IQR) 0 (0-224.98)
Total cost 277,096.40
Mean total cost 8938.60
Median total cost (IQR) 8423.00
(6869.92-9370.1
Figures represent total values in US dollars. Bed occupancy was calculate
24-h period. Suitability for discharge from the intensive care unit (ICU) a
judgment of independent anesthetic intensive care staff. Transfusion cost
costs were calculated as the costs for staff, including intra-aortic balloon p
room staff overtime costs. P values were derived from the Mann-Whitney
platelets; No., numbers of units of blood, shifts, or procedures performedof avoiding homologous blood exposure will only increase.
26 The Journal of Thoracic and Cardiovascular Surgery ● July 2Second, cell salvage is a relatively inexpensive cell-conser-
vation modality. Mechanical cell salvage in many of our
patients resulted in only 13% of patients requiring red blood
cell transfusion, compared with 10% in a randomized trial
Autotransfusion (n  30)
Median difference
(95% CI) P value
No. Total cost
30 6815.54
16,615.2
30 2208.00
36 677.64
30
20 3588.00
29,904.40
996.80
1030.00
(933.57-1029.84)
156.4
(156.4 to137.6)
.0001
24-h shifts Total cost
29 115,456.00
58 72,142.70
220 79,037.20
266,636.00
8887.90
8113.00
(6371.81-10,365.18)
884.6
(2155.6 to 332.1)
.13
No. Total cost
3 590.64
3369.04
3959.68
132.00
0 (0-0) 0 (0 to 0) .69
No. Total cost
7 1571.36
3 938.40
0 0
2509.76
83.70
0 (0-0) 0 (0 to 0) .13
303,010.00
10,100.34
9244.00
(7603.50-11,373.43)
1015.9
(2260.0 to 206.1)
.12
ording to nursing shifts at each dependency level, which was costed per
gh-dependency unit (HDU) followed unit protocol and was based on the
e calculated from number of units transfused. Postoperative management
(IABP), vacuum wound dressings, radiologic investigations, and operating
BC, Packed leukodepleted red blood cells; FFP, fresh frozen plasma; PLT,
number of patients); IQR, interquartile range; CI, confidence interval.)
4)
8)
d acc
nd hi
s wer
umps
test. Rof aprotinin in OPCAB (2 106 KIU loading dose followed
005
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operation).26 The cost of intraoperative cell salvage in our
study was, however, less expensive per patient than aproti-
nin therapy ($118.30 vs $261.55, respectively). Cell salvage
and autologous blood transfusion may also avoid throm-
botic complications that have been attributed to aprotinin
use.27 Acute normovolemic hemodilution combined with
intraoperative tranexamic acid administration and, on de-
mand, intraoperative reinfusion of shed blood (in 39% of
patients) reduced homologous blood use from 20% to 4% in
a randomized trial.28 Cell-saver use was operator depen-
dent, however, and was therefore a potential source of bias.
Also, although both acute normovolemic hemodilution and
tranexamic acid are inexpensive, the use of cell salvage will
have increased the cost considerably. The relative cost-effec-
tiveness of this and other strategies merit further analyses.
A potential criticism of this study is that the ICU staff
were not blinded to treatment allocation. There is a recog-
nized tendency to avoid homologous blood in patients in
whom cell salvage devices are used,29 and the unblinded
nature of the study may have led to bias. Intraoperative cell
salvage is used routinely in OPCAB patients at our institu-
tion, however, and strict local guidelines are used to make
decisions about perioperative clinical management, thus
making this less likely.
In conclusion, intraoperative cell salvage and autotransfu-
sion in OPCAB surgery is associated with a modest clinical
benefit, without increased risk to patients or significantly in-
creased costs. As homologous blood becomes more expensive,
the relative cost-effectiveness of this technique will increase.
This study supports its routine use in OPCAB surgery, al-
though its precise role as part of a multimodality red blood
cell conservation strategy in OPCAB remains to be defined.
We are grateful to Dr Raimondo Ascione, Franco Ciulli, and
Jon Hutter for permitting their patients to be enrolled in this study
and for the assistance of the Departments of Perfusion, Cardiotho-
racic Anaesthesia, and Intensive Care.
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